Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel liposome versus paclitaxel plus carboplatin as first-line chemotherapy for ovarian cancer
ChiCTR2000038555Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Dec 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of liposomal paclitaxel, paclitaxel and carboplatin in ovarian cancer (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Progression-free survival. Started Dec 2016; status: recruiting.
02
Drugs
liposomal paclitaxelpaclitaxelcarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000038555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038555.